The role of C-reactive protein as a prognostic marker in COVID-19
暂无分享,去创建一个
J. Hewitt | T. Quinn | B. Carter | P. Myint | A. Verduri | G. Guaraldi | Dominic Stringer | P. Braude | A. Vilches-Moraga | L. Pearce | M. Stechman | A. Price | J. Collins | E. Bruce | A. Einarsson | F. Rickard | M. Holloway | J. Hesford | F. Barlow-Pay | S. Moug | K. McCarthy | T. Telford | Sandeep Singh | C. Murphy | N. Galbraith | T. Kneen | J. Kelly | C. Bisset | R. Simmons | S. Duffy | L. Evans | R. Alexander | Ā. McGovern | Sheila Jones | C. Davey | K. Lunstone | A. Cavenagh | C. Silver | D. Paxton | W. Harris | E. Bhatti | J. Edwards | Madeline Garcia | S. Sangani | Thomas Lee | Eilidh Alice Aine Carly Ross Giovanni Caroline Joanna Tar Bruce Einarsson McGovern Bisset Alexander | Tarik El Jichi Mutasem | E. Mitchel | S. Moug
[1] J. Hewitt,et al. Study protocol for the COPE study: COVID-19 in Older PEople: the influence of frailty and multimorbidity on survival. A multicentre, European observational study , 2020, BMJ Open.
[2] J. Preller,et al. Clinical features and inpatient trajectories of older inpatients with COVID-19: a retrospective observational study. , 2020 .
[3] M. Kivimäki,et al. Overweight, obesity, and risk of hospitalization for COVID-19: A community-based cohort study of adults in the United Kingdom , 2020, Proceedings of the National Academy of Sciences.
[4] Mahdad Noursadeghi,et al. Systematic evaluation and external validation of 22 prognostic models among hospitalised adults with COVID-19: an observational cohort study , 2020, European Respiratory Journal.
[5] D. MacFadden,et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis , 2020, Clinical Microbiology and Infection.
[6] Yusuke Nakamura,et al. SARS-CoV-2 genomic variations associated with mortality rate of COVID-19 , 2020, Journal of Human Genetics.
[7] E. Kandil,et al. Diagnostic and prognostic value of hematological and immunological markers in COVID-19 infection: A meta-analysis of 6320 patients , 2020, medRxiv.
[8] J. Hewitt,et al. The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study , 2020, The Lancet Public Health.
[9] Nurshad Ali. Elevated level of C‐reactive protein may be an early marker to predict risk for severity of COVID‐19 , 2020, Journal of medical virology.
[10] P. Horby,et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study , 2020, BMJ.
[11] Wei Li,et al. The value of clinical parameters in predicting the severity of COVID‐19 , 2020, Journal of medical virology.
[12] Xin-ran Ji,et al. Validation of Predictors of Disease Severity and Outcomes in COVID-19 Patients: A Descriptive and Retrospective Study , 2020, Med.
[13] B. Lipworth,et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19 , 2020, Journal of Allergy and Clinical Immunology.
[14] Wei Chen,et al. Plasma CRP level is positively associated with the severity of COVID-19 , 2020, Annals of Clinical Microbiology and Antimicrobials.
[15] Z. Wang,et al. Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: A retrospective case-control study , 2020, EClinicalMedicine.
[16] Fang Liu,et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19 , 2020, Journal of Clinical Virology.
[17] Dong Liu,et al. Tocilizumab treatment in COVID‐19: A single center experience , 2020, Journal of medical virology.
[18] Ting Yu,et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.
[19] S. Pati,et al. Physiological markers and multimorbidity , 2018, Journal of comorbidity.
[20] A. Badawi,et al. C-reactive protein as a biomarker of severe H1N1 influenza , 2018, Inflammation Research.
[21] A. Markanday. Acute Phase Reactants in Infections: Evidence-Based Review and a Guide for Clinicians , 2015, Open forum infectious diseases.
[22] S. Pocock,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies , 2007, The Lancet.
[23] Matthias Egger,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies , 2007, PLoS medicine.
[24] W. Sauerbrei,et al. Confidence intervals for the effect of a prognostic factor after selection of an ‘optimal’ cutpoint , 2004, Statistics in medicine.
[25] Mark B Pepys,et al. C-reactive protein: a critical update. , 2003, The Journal of clinical investigation.
[26] Kuo-Chien Tsao,et al. Development of ELISA on microplate for serum C-reactive protein and establishment of age-dependent normal reference range. , 2002, Clinica chimica acta; international journal of clinical chemistry.
[27] F. Harrell,et al. Evaluating the yield of medical tests. , 1982, JAMA.
[28] H. Akaike. A new look at the statistical model identification , 1974 .
[29] S. Suner,et al. C-reactive protein as predictor of bacterial infection among patients with an influenza-like illness. , 2013, The American journal of emergency medicine.